Frontier Capital Management CO LLC Exelixis, Inc. Transaction History

Frontier Capital Management CO LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $54.4 Million - $67.9 Million	-3,592,384 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $9.78 Million - $12.5 Million	553,150 Added 18.2%	3,592,384 $63.5 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $4.11 Million - $5.37 Million	217,026 Added 7.69%	3,039,234 $64.9 Million
Q1 2019 May 07, 2019	BUY	$19.6 - $24.76 $43 Million - $54.4 Million	2,196,279 Added 350.88%	2,822,208 $67.2 Million
Q4 2018 Jan 25, 2019	BUY	$13.65 - $21.8 $8.54 Million - $13.6 Million	625,929 New	625,929 $12.3 Million

459

246M

1.7M

1.02M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.23B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Frontier Capital Management CO LLC with notifications on news.